Skip to content

NAF has launched a petition on Change.org calling on the FDA to prioritize treatment options for rare diseases with urgent unmet needs, including Spinocerebellar Ataxia (SCA)
 SIGN THE PETITION

Dr. Chandrakanth Edamakanti

Staff Writer

Chicago, Illinois, USA

I am Chandrakanth Edamakanti. I received my PhD from the University of Würzburg in neurology. In 2014, I joined the lab of Dr. Puneet Opal at Northwestern University as a Post-Doc. My research focuses are on understanding the early pathological derailments that drive the disease pathogenesis in adult-onset, neurodegenerative disorders, specifically a polyglutamine disorder called Spinocerebellar Ataxia Type 1 (SCA1). My primary focus is to explore the existence of plausible, non-cell autonomous toxicity (non-neuronal or neuronal) of Purkinje cells before the disease onset.

Translate »

Join the Ataxia community today!

Become a free member for exclusive content from NAF.